Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression.
about
TYK2 is a key regulator of the surveillance of B lymphoid tumorsBCR/ABL-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR/ABL-positive cellsLoss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor SurveillanceNew approaches in the immunotherapy of haematological malignancies.Differential and opposing effects of imatinib on LPS- and ventilator-induced lung injury.Natural killer cell-triggering receptors in patients with acute leukaemia.Targeting GSK-3: a promising approach for cancer therapy?Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway.Toll-like receptors and their role in carcinogenesis and anti-tumor treatment.Novel immune modulators used in hematology: impact on NK cellsIron chelation in the treatment of cancer: a new role for deferasirox?Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications.The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive LeukemiasMultidrug-resistant cancer cells and cancer stem cells hijack cellular systems to circumvent systemic therapies, can natural products reverse this?NK cells sense tumors, course of disease and treatments: Consequences for NK-based therapies.Chronic myeloid leukemia and allogeneic natural killer cells: a surprising dialogue.N-Myc-Interacting Protein Negatively Regulates TNF-α-Induced NF-κB Transcriptional Activity by Sequestering NF-κB/p65 in the Cytoplasm.NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice.Defects of immune surveillance offer new insights into the pathophysiology and therapy of myelodysplastic syndromes
P2860
Q24559982-362A5F4C-8C2C-40DB-A841-2906D4DF0BE7Q28304582-AA39FD58-33C3-4FEB-B4EF-B4AB166CE79CQ35086418-B09BE4C1-B0F8-4055-BF42-5458FDAFCC0BQ35106657-0FCBE8A9-7975-413E-A366-D9CABA3660F5Q35115797-22A94DB7-1956-4539-9A0F-21EBBE782359Q35614641-19FF8EB7-3287-4F97-935F-5726339282BBQ36429679-87434DE2-4CD3-44AC-B930-05434FE6D1F0Q36705250-6717F01E-444C-4440-B694-FC44DFB7D15BQ37354939-064D533D-03BA-43B6-BF6E-488DD85A4D4DQ38073760-62CC8E7B-4E38-4733-A972-E513CDBCED55Q38112400-1FBDBDC0-A9D5-4337-81FD-DFE85B33590AQ38658670-2687790E-958A-4F34-8514-EC88A67EF786Q38937733-32E34984-9D5C-483B-86F9-A793488A9795Q38953085-398FF8DA-5181-459E-8D41-902EE9BC50AEQ41967990-7807EA3B-B0DE-4C53-8B53-848D9FAD21D7Q43061582-F7277E88-8158-434E-AD89-A69D39B19721Q46322446-BC6CFA28-36CC-4B46-B102-37066EAC1470Q54561974-07155F72-9F32-423B-88D8-35A403CC6085Q58621131-CFB4982C-8B99-4E7A-AF2A-8DE6C3185F1C
P2860
Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Leukemic target susceptibility ...... nship with BCR-ABL expression.
@en
type
label
Leukemic target susceptibility ...... nship with BCR-ABL expression.
@en
prefLabel
Leukemic target susceptibility ...... nship with BCR-ABL expression.
@en
P2093
P356
P1433
P1476
Leukemic target susceptibility ...... nship with BCR-ABL expression.
@en
P2093
Ali G Turhan
Bruno Azzarone
Frédéric Baron
Jean Henri Bourhis
Julien Giron-Michel
Mohamed Bentires-Alj
Salem Chouaib
P304
P356
10.1182/BLOOD.V99.6.2107
P407
P577
2002-03-01T00:00:00Z